Pharmaceutical leaders reportedly convened urgently after Trumpβs election win and RFK Jr.βs pledge to βgutβ the FDAβs nutrition division.
Following President-elect Donald Trumpβs victory, executives from the top five pharmaceutical companies reportedly held an emergency meeting to discuss potential regulatory shake-ups. Concerns have intensified with Robert F. Kennedy Jr., an outspoken critic of federal health agencies, set to play a significant role in restructuring public health regulations under the new administration.
Jamel Holley, a New Jersey assemblyman and advisor to Kennedy, stated, βThe top CEOs are in a state of panic,β adding that the teleconference addressed a new βthreat environmentβ as the pharmaceutical sector braces for major policy shifts.
